Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | qPCR, RNAi, Western blot, MTT assay etc. |
| Sample | NPC tissues, cell lines (NP69 and N5-Tert) |
| Expression Pattern | up-regulated |
| Function Description | In this study, we report that LncRNA ANRIL generally up-regulated in nasopharyngeal carcinoma. ANRIL was highly expressed in advanced-stage cancer. Further investigation showed that knockdown of ANRIL significantly repressed NPC cell proliferation and transformation. We also found that ANRIL could induce the percentage of side population cells (SP cells) in NPC. |
| Pubmed ID | 27557514 |
| Year | 2016 |
| Title | LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells. |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for nasopharyngeal cancer | OMIM COSMIC |